Alcohol can intensify the blood-pressure-lowering effect of tadalafil and increase the likelihood of dizziness. Moderate consumption is unlikely to cause serious problems, but heavy drinking should be avoided around the time you take the tablet.
Tadalafil’s vasodilatory effect can last up to 36 hours, while dapoxetine’s action on ejaculation typically persists for 4-6 hours after ingestion. The combined benefit therefore covers the window of sexual activity for most users.
A erection lasting longer than four hours (priapism) is a medical emergency. Seek immediate urgent care; do not wait for it to resolve on its own.
Men with well-controlled hypertension may use the medication, but those with severe uncontrolled blood pressure should avoid it. Blood pressure should be measured before starting therapy.
The product contains tadalafil and dapoxetine, both of which are indicated for men’s sexual health conditions. It is not licensed for use in women.
Dapoxetine is an SSRI and can increase the risk of serotonin syndrome when combined with other serotonergic agents (e.g., other SSRIs, SNRIs, MAO inhibitors). Discuss all psychiatric medications with your prescriber.
Keep the bottle in its original packaging, away from heat and moisture. A carry-on bag is preferable to avoid temperature extremes in checked luggage.
Both tadalafil and dapoxetine are prescription-only medicines in the UK. Because Super Tadapox is an unlicensed combination, a qualified prescriber must specially authorize its use.
The combined tablet offers convenience and synchronized timing. Pharmacologically, the effects are the same as taking each drug alone; however, safety monitoring should consider the additive impact on blood pressure and serotonin pathways.
Having a cardiac device does not automatically preclude use, but underlying heart disease must be evaluated. Discuss your cardiac history with a cardiologist before starting therapy.
Super Tadapox is a brand-named combination pill that contains two active ingredients: tadalafil (40 mg) and dapoxetine (60 mg). The product is formulated as a single oral tablet and is marketed for adults who experience both erectile dysfunction (ED) and premature ejaculation (PE). In the United Kingdom, Super Tadapox is not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) as a combined therapy; each component is approved separately (tadalafil for ED, dapoxetine for PE). Consequently, prescribing and dispensing of Super Tadapox must be undertaken by a qualified healthcare professional who can assess suitability and monitor safety.
Tadalafil blocks the enzyme PDE5, which normally breaks down cyclic guanosine monophosphate (cG-MP) in the smooth muscle of the penis. By inhibiting PDE5, cG-MP levels remain elevated, leading to relaxation of the penile arteries, increased blood flow, and the ability to achieve an erection in response to sexual stimulation. The effect typically begins within 30 minutes and can last up to 36 hours, which is why tadalafil is sometimes called “the weekend pill.”
Dapoxetine increases the amount of serotonin available at the synapse by preventing its re-uptake. Elevated serotonin activity in the central nervous system delays the ejaculatory reflex, allowing men to prolong intercourse. Unlike traditional SSRIs used for depression, dapoxetine has a rapid onset (approximately 1-2 hours) and a short elimination half-life (≈19 hours), making it suitable for on-demand use before sexual activity.
When taken together, the tadalafil component supports the physical ability to achieve and maintain an erection, while the dapoxetine component helps delay ejaculation. The two mechanisms act on separate physiological pathways, offering a potential dual benefit for men who experience both conditions simultaneously.
| Approved indication (individual component) | Typical patient profile | ||--| | Erectile Dysfunction (tadalafil) | Men with vascular or neurogenic causes of difficulty achieving an erection. | | Premature Ejaculation (dapoxetine) | Men who ejaculate within 1-2 minutes of penetration and desire longer sexual activity. |
Super Tadapox is not an MHRA-approved product; its use for combined ED + PE therapy is considered off-label and must be supervised by a prescriber.
The combination of a PDE5 inhibitor with a short-acting SSRI has been studied in a limited number of clinical trials. Some evidence suggests that co-administration improves patient-reported satisfaction compared with either agent alone. However, these studies are small, and the formulation is not formally evaluated for safety or efficacy by UK regulators.
Disclaimer: Off-label use of Super Tadapox requires careful medical supervision, individualized risk assessment, and ongoing monitoring for adverse effects.
General advice: Patients should disclose all prescription, over-the-counter, herbal, and dietary supplements before starting Super Tadapox.
Note: Dosing details above are based on the listed 40/60 mg tablet strength and general prescribing principles. Final dosing must be individualized by a prescriber.
This article provides educational information about Super Tadapox and is not a substitute for professional medical advice. Treatment decisions, including the use of unapproved or off-label therapies, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
